Published in Cancer on July 01, 1979
Head and neck cancer: an evolving treatment paradigm. Cancer (2008) 1.21
Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1.13
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr (2007) 1.12
[Induction chemotherapy with cis-platinum in head and neck tumors. First clinical and histopathologic findings (author's transl)]. Arch Otorhinolaryngol (1981) 0.85
Systemic therapy in head and neck cancer: changing paradigm. Indian J Surg Oncol (2012) 0.77
Proliferative activity following induction chemotherapy in squamous cell carcinoma of the head and neck. A histopathological and immunohistochemical study using monoclonal antibodies. Eur Arch Otorhinolaryngol (1991) 0.75
The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am (2013) 0.75
Update in cancer chemotherapy: head and neck cancer, Part 2. J Natl Med Assoc (1986) 0.75
Head and neck cancer. N Engl J Med (1993) 6.33
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst (1998) 3.17
Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst (1997) 3.03
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (2000) 2.39
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Laser surgery in the larynx. Early clinical experience with continuous CO 2 laser. Ann Otol Rhinol Laryngol (1972) 2.25
Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst (2001) 2.18
Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst (1998) 2.16
Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst (1994) 2.15
Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst (2001) 2.13
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.98
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer (1998) 1.97
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.81
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res (2000) 1.81
Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst (1997) 1.79
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst (1992) 1.79
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst (1998) 1.78
Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med (1995) 1.76
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 1.76
Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst (1990) 1.61
Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res (1994) 1.57
The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol (1992) 1.57
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst (2001) 1.55
Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. J Neurosci (1998) 1.54
Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med (1991) 1.52
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2001) 1.50
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 1.47
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer (1995) 1.47
Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst (1998) 1.46
Preliminary clinical results of window partial laryngectomy: a combined endoscopic and open technique. Ann Otol Rhinol Laryngol (2000) 1.46
Reduced DNA repair capacity in lung cancer patients. Cancer Res (1996) 1.44
Field cancerization in the aerodigestive tract--its etiology, manifestation, and significance. J Otolaryngol (1984) 1.43
Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res (1993) 1.43
Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene (1999) 1.41
Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys (1995) 1.40
Chemoprevention strategies for lung and upper aerodigestive tract cancer. Cancer Res (1992) 1.39
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am (1997) 1.39
Jet ventilation in upper airway obstruction: description and model lung testing of a new jetting device. Anesth Analg (1998) 1.39
Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst (1993) 1.38
Opioid inhibition of rat periaqueductal grey neurones with identified projections to rostral ventromedial medulla in vitro. J Physiol (1996) 1.38
Molecular markers of the risk of oral cancer. N Engl J Med (2001) 1.38
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res (2001) 1.37
Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys (1989) 1.34
Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology (1985) 1.34
Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res (2000) 1.33
Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol (2001) 1.33
Association of the Epstein-Barr virus with lymphoepithelioma of the thymus. Cancer (1988) 1.31
Lactic acidosis in oat cell carcinoma with extensive hepatic metastases. Arch Intern Med (1978) 1.31
Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys (1989) 1.30
Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol (1986) 1.30
Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene (1998) 1.29
Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev (1998) 1.28
muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci U S A (2006) 1.26
Laser surgery in otolaryngology: interaction of CO2 laser and soft tissue. Ann N Y Acad Sci (1976) 1.26
Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis (2000) 1.26
Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev (2000) 1.25
The evolution of mature teratoma from malignant testicular tumors. Cancer (1977) 1.24
Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res (2001) 1.24
Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br J Pharmacol (1996) 1.23
Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res (1996) 1.23
Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg (2001) 1.23
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol (1995) 1.22
Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene (1997) 1.22
DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res (1996) 1.22
Vocal cord nodules and polyps--the role of surgical treatment. Laryngoscope (1971) 1.21
Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res (1999) 1.20
Predictive factors of success or failure in the endoscopic management of laryngeal and tracheal stenosis. Ann Otol Rhinol Laryngol (1982) 1.19
"External counterpressure" and "internal distention" for optimal laryngoscopic exposure of the anterior glottal commissure. Ann Otol Rhinol Laryngol (1994) 1.19
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst (1997) 1.19
Microscopic laryngoscopy. A review and appraisal. Laryngoscope (1970) 1.16
Inguinal node metastases from testicular tumors in patients with prior orchiopexy. J Urol (1983) 1.16
Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol (1976) 1.16
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol (2000) 1.16
Symptoms in early head and neck cancer: an inadequate indicator. Otolaryngol Head Neck Surg (1998) 1.15
Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr (1996) 1.15
Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res (1994) 1.15
Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl (1998) 1.15
Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene (1998) 1.15
Localized amyloidosis of the head and neck and upper aerodigestive and lower respiratory tracts. Ann Otol Rhinol Laryngol (1984) 1.14
Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res (1994) 1.14
Toluidine blue in the management of carcinoma of the oral cavity. Arch Otolaryngol (1968) 1.13